Antiviral activities of type I interferons to SARS-CoV-2 infection
There is an urgent need to identify antivirals to curtail the COVID-19 pandemic. Herein, we report the sensitivity of SARS-CoV-2 to recombinant human interferons α and β (IFNα/β). Treatment with IFN-α or IFN-β at a concentration of 50 international units (IU) per milliliter reduces viral titers by 3...
Gespeichert in:
| Veröffentlicht in: | Antiviral research 2020-07, Vol.179, p.104811-104811, Article 104811 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 104811 |
|---|---|
| container_issue | |
| container_start_page | 104811 |
| container_title | Antiviral research |
| container_volume | 179 |
| creator | Mantlo, Emily Bukreyeva, Natalya Maruyama, Junki Paessler, Slobodan Huang, Cheng |
| description | There is an urgent need to identify antivirals to curtail the COVID-19 pandemic. Herein, we report the sensitivity of SARS-CoV-2 to recombinant human interferons α and β (IFNα/β). Treatment with IFN-α or IFN-β at a concentration of 50 international units (IU) per milliliter reduces viral titers by 3.4 log or over 4 log, respectively, in Vero cells. The EC50 of IFN-α and IFN-β treatment is 1.35 IU/ml and 0.76 IU/ml, respectively, in Vero cells. These results suggest that SARS-CoV-2 is more sensitive than many other human pathogenic viruses, including SARS-CoV. Overall, our results demonstrate the potential efficacy of human Type I IFN in suppressing SARS-CoV-2 infection, a finding which could inform future treatment options for COVID-19.
•Type I Interferons inhibit SARS-CoV-2, the causative agent for COVID-19, in cultured cells.•Treatment with IFN-α or IFN-β at 50 IU/ml reduces viral titers by 3.4-log or over 4-log, respectively, in Vero cells.•The EC50 of IFN-α and IFN-β treatment is 1.35 IU/ml and 0.76 IU/ml, respectively, in Vero cells.•Type I IFNs have been used in clinical therapies and thus could be repurposed in COVID-19 treatment. |
| doi_str_mv | 10.1016/j.antiviral.2020.104811 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7188648</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0166354220302254</els_id><sourcerecordid>2398154165</sourcerecordid><originalsourceid>FETCH-LOGICAL-c541t-e869f1b4a640463128252df4f0b37c81cc5e89709cae98ca102d087c807721123</originalsourceid><addsrcrecordid>eNqFUctOwzAQtBCIlscvQI5cUrxO4jgXpFDxqFQJiQJXy3U24KqNi51W6t_jKm0FJ05eeWZnRzOEXAMdAAV-OxuopjVr49R8wCjb_qYC4Ij0QeQsLmjBj0k_MHmcZCnrkTPvZ5RSnhfilPQSlnAKgvXJfbnXiZTeTq1BH9k6ajdLjEaRaVp0NTrb-Ki10aR8ncRD-xGzgNQYNmxzQU5qNfd4uXvPyfvjw9vwOR6_PI2G5TjWWQptjIIXNUxTxVOa8gSYYBmr6rSm0yTXArTOUBQ5LbTCQmgFlFVUBITmOQNgyTm563SXq-kCK41NG2zLpTML5TbSKiP_Io35kp92LXMQgqciCNzsBJz9XqFv5cJ4jfO5atCuvGRJISB45Vmg5h1VO-u9w_pwBqjcNiBn8tCA3DYguwbC5tVvl4e9feSBUHYEDFmtDTrptcFGY2VcCFRW1vx75AfSrZr-</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2398154165</pqid></control><display><type>article</type><title>Antiviral activities of type I interferons to SARS-CoV-2 infection</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Mantlo, Emily ; Bukreyeva, Natalya ; Maruyama, Junki ; Paessler, Slobodan ; Huang, Cheng</creator><creatorcontrib>Mantlo, Emily ; Bukreyeva, Natalya ; Maruyama, Junki ; Paessler, Slobodan ; Huang, Cheng</creatorcontrib><description>There is an urgent need to identify antivirals to curtail the COVID-19 pandemic. Herein, we report the sensitivity of SARS-CoV-2 to recombinant human interferons α and β (IFNα/β). Treatment with IFN-α or IFN-β at a concentration of 50 international units (IU) per milliliter reduces viral titers by 3.4 log or over 4 log, respectively, in Vero cells. The EC50 of IFN-α and IFN-β treatment is 1.35 IU/ml and 0.76 IU/ml, respectively, in Vero cells. These results suggest that SARS-CoV-2 is more sensitive than many other human pathogenic viruses, including SARS-CoV. Overall, our results demonstrate the potential efficacy of human Type I IFN in suppressing SARS-CoV-2 infection, a finding which could inform future treatment options for COVID-19.
•Type I Interferons inhibit SARS-CoV-2, the causative agent for COVID-19, in cultured cells.•Treatment with IFN-α or IFN-β at 50 IU/ml reduces viral titers by 3.4-log or over 4-log, respectively, in Vero cells.•The EC50 of IFN-α and IFN-β treatment is 1.35 IU/ml and 0.76 IU/ml, respectively, in Vero cells.•Type I IFNs have been used in clinical therapies and thus could be repurposed in COVID-19 treatment.</description><identifier>ISSN: 0166-3542</identifier><identifier>EISSN: 1872-9096</identifier><identifier>DOI: 10.1016/j.antiviral.2020.104811</identifier><identifier>PMID: 32360182</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Animals ; Antiviral Agents - pharmacology ; Antiviral therapy ; Betacoronavirus - drug effects ; Chlorocebus aethiops ; Coronavirus Infections - drug therapy ; Coronavirus Infections - immunology ; Coronavirus Infections - virology ; COVID-19 ; Humans ; Immunity, Innate ; Innate immune ; Interferon ; Interferon Type I - pharmacology ; Interferon-alpha - pharmacology ; Interferon-beta - pharmacology ; Pandemics ; Pneumonia, Viral - drug therapy ; Pneumonia, Viral - immunology ; Pneumonia, Viral - virology ; Recombinant Proteins - pharmacology ; SARS-CoV-2 ; Severe Acute Respiratory Syndrome - drug therapy ; Severe Acute Respiratory Syndrome - immunology ; Severe Acute Respiratory Syndrome - virology ; Vero Cells ; Viral Load - drug effects ; Virus Replication - drug effects</subject><ispartof>Antiviral research, 2020-07, Vol.179, p.104811-104811, Article 104811</ispartof><rights>2020 Elsevier B.V.</rights><rights>Copyright © 2020 Elsevier B.V. All rights reserved.</rights><rights>2020 Elsevier B.V. All rights reserved. 2020 Elsevier B.V.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c541t-e869f1b4a640463128252df4f0b37c81cc5e89709cae98ca102d087c807721123</citedby><cites>FETCH-LOGICAL-c541t-e869f1b4a640463128252df4f0b37c81cc5e89709cae98ca102d087c807721123</cites><orcidid>0000-0003-0088-4793 ; 0000-0001-6413-2334 ; 0000-0001-5402-353X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.antiviral.2020.104811$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32360182$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mantlo, Emily</creatorcontrib><creatorcontrib>Bukreyeva, Natalya</creatorcontrib><creatorcontrib>Maruyama, Junki</creatorcontrib><creatorcontrib>Paessler, Slobodan</creatorcontrib><creatorcontrib>Huang, Cheng</creatorcontrib><title>Antiviral activities of type I interferons to SARS-CoV-2 infection</title><title>Antiviral research</title><addtitle>Antiviral Res</addtitle><description>There is an urgent need to identify antivirals to curtail the COVID-19 pandemic. Herein, we report the sensitivity of SARS-CoV-2 to recombinant human interferons α and β (IFNα/β). Treatment with IFN-α or IFN-β at a concentration of 50 international units (IU) per milliliter reduces viral titers by 3.4 log or over 4 log, respectively, in Vero cells. The EC50 of IFN-α and IFN-β treatment is 1.35 IU/ml and 0.76 IU/ml, respectively, in Vero cells. These results suggest that SARS-CoV-2 is more sensitive than many other human pathogenic viruses, including SARS-CoV. Overall, our results demonstrate the potential efficacy of human Type I IFN in suppressing SARS-CoV-2 infection, a finding which could inform future treatment options for COVID-19.
•Type I Interferons inhibit SARS-CoV-2, the causative agent for COVID-19, in cultured cells.•Treatment with IFN-α or IFN-β at 50 IU/ml reduces viral titers by 3.4-log or over 4-log, respectively, in Vero cells.•The EC50 of IFN-α and IFN-β treatment is 1.35 IU/ml and 0.76 IU/ml, respectively, in Vero cells.•Type I IFNs have been used in clinical therapies and thus could be repurposed in COVID-19 treatment.</description><subject>Animals</subject><subject>Antiviral Agents - pharmacology</subject><subject>Antiviral therapy</subject><subject>Betacoronavirus - drug effects</subject><subject>Chlorocebus aethiops</subject><subject>Coronavirus Infections - drug therapy</subject><subject>Coronavirus Infections - immunology</subject><subject>Coronavirus Infections - virology</subject><subject>COVID-19</subject><subject>Humans</subject><subject>Immunity, Innate</subject><subject>Innate immune</subject><subject>Interferon</subject><subject>Interferon Type I - pharmacology</subject><subject>Interferon-alpha - pharmacology</subject><subject>Interferon-beta - pharmacology</subject><subject>Pandemics</subject><subject>Pneumonia, Viral - drug therapy</subject><subject>Pneumonia, Viral - immunology</subject><subject>Pneumonia, Viral - virology</subject><subject>Recombinant Proteins - pharmacology</subject><subject>SARS-CoV-2</subject><subject>Severe Acute Respiratory Syndrome - drug therapy</subject><subject>Severe Acute Respiratory Syndrome - immunology</subject><subject>Severe Acute Respiratory Syndrome - virology</subject><subject>Vero Cells</subject><subject>Viral Load - drug effects</subject><subject>Virus Replication - drug effects</subject><issn>0166-3542</issn><issn>1872-9096</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUctOwzAQtBCIlscvQI5cUrxO4jgXpFDxqFQJiQJXy3U24KqNi51W6t_jKm0FJ05eeWZnRzOEXAMdAAV-OxuopjVr49R8wCjb_qYC4Ij0QeQsLmjBj0k_MHmcZCnrkTPvZ5RSnhfilPQSlnAKgvXJfbnXiZTeTq1BH9k6ajdLjEaRaVp0NTrb-Ki10aR8ncRD-xGzgNQYNmxzQU5qNfd4uXvPyfvjw9vwOR6_PI2G5TjWWQptjIIXNUxTxVOa8gSYYBmr6rSm0yTXArTOUBQ5LbTCQmgFlFVUBITmOQNgyTm563SXq-kCK41NG2zLpTML5TbSKiP_Io35kp92LXMQgqciCNzsBJz9XqFv5cJ4jfO5atCuvGRJISB45Vmg5h1VO-u9w_pwBqjcNiBn8tCA3DYguwbC5tVvl4e9feSBUHYEDFmtDTrptcFGY2VcCFRW1vx75AfSrZr-</recordid><startdate>20200701</startdate><enddate>20200701</enddate><creator>Mantlo, Emily</creator><creator>Bukreyeva, Natalya</creator><creator>Maruyama, Junki</creator><creator>Paessler, Slobodan</creator><creator>Huang, Cheng</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0088-4793</orcidid><orcidid>https://orcid.org/0000-0001-6413-2334</orcidid><orcidid>https://orcid.org/0000-0001-5402-353X</orcidid></search><sort><creationdate>20200701</creationdate><title>Antiviral activities of type I interferons to SARS-CoV-2 infection</title><author>Mantlo, Emily ; Bukreyeva, Natalya ; Maruyama, Junki ; Paessler, Slobodan ; Huang, Cheng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c541t-e869f1b4a640463128252df4f0b37c81cc5e89709cae98ca102d087c807721123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Animals</topic><topic>Antiviral Agents - pharmacology</topic><topic>Antiviral therapy</topic><topic>Betacoronavirus - drug effects</topic><topic>Chlorocebus aethiops</topic><topic>Coronavirus Infections - drug therapy</topic><topic>Coronavirus Infections - immunology</topic><topic>Coronavirus Infections - virology</topic><topic>COVID-19</topic><topic>Humans</topic><topic>Immunity, Innate</topic><topic>Innate immune</topic><topic>Interferon</topic><topic>Interferon Type I - pharmacology</topic><topic>Interferon-alpha - pharmacology</topic><topic>Interferon-beta - pharmacology</topic><topic>Pandemics</topic><topic>Pneumonia, Viral - drug therapy</topic><topic>Pneumonia, Viral - immunology</topic><topic>Pneumonia, Viral - virology</topic><topic>Recombinant Proteins - pharmacology</topic><topic>SARS-CoV-2</topic><topic>Severe Acute Respiratory Syndrome - drug therapy</topic><topic>Severe Acute Respiratory Syndrome - immunology</topic><topic>Severe Acute Respiratory Syndrome - virology</topic><topic>Vero Cells</topic><topic>Viral Load - drug effects</topic><topic>Virus Replication - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mantlo, Emily</creatorcontrib><creatorcontrib>Bukreyeva, Natalya</creatorcontrib><creatorcontrib>Maruyama, Junki</creatorcontrib><creatorcontrib>Paessler, Slobodan</creatorcontrib><creatorcontrib>Huang, Cheng</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Antiviral research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mantlo, Emily</au><au>Bukreyeva, Natalya</au><au>Maruyama, Junki</au><au>Paessler, Slobodan</au><au>Huang, Cheng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antiviral activities of type I interferons to SARS-CoV-2 infection</atitle><jtitle>Antiviral research</jtitle><addtitle>Antiviral Res</addtitle><date>2020-07-01</date><risdate>2020</risdate><volume>179</volume><spage>104811</spage><epage>104811</epage><pages>104811-104811</pages><artnum>104811</artnum><issn>0166-3542</issn><eissn>1872-9096</eissn><abstract>There is an urgent need to identify antivirals to curtail the COVID-19 pandemic. Herein, we report the sensitivity of SARS-CoV-2 to recombinant human interferons α and β (IFNα/β). Treatment with IFN-α or IFN-β at a concentration of 50 international units (IU) per milliliter reduces viral titers by 3.4 log or over 4 log, respectively, in Vero cells. The EC50 of IFN-α and IFN-β treatment is 1.35 IU/ml and 0.76 IU/ml, respectively, in Vero cells. These results suggest that SARS-CoV-2 is more sensitive than many other human pathogenic viruses, including SARS-CoV. Overall, our results demonstrate the potential efficacy of human Type I IFN in suppressing SARS-CoV-2 infection, a finding which could inform future treatment options for COVID-19.
•Type I Interferons inhibit SARS-CoV-2, the causative agent for COVID-19, in cultured cells.•Treatment with IFN-α or IFN-β at 50 IU/ml reduces viral titers by 3.4-log or over 4-log, respectively, in Vero cells.•The EC50 of IFN-α and IFN-β treatment is 1.35 IU/ml and 0.76 IU/ml, respectively, in Vero cells.•Type I IFNs have been used in clinical therapies and thus could be repurposed in COVID-19 treatment.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>32360182</pmid><doi>10.1016/j.antiviral.2020.104811</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0003-0088-4793</orcidid><orcidid>https://orcid.org/0000-0001-6413-2334</orcidid><orcidid>https://orcid.org/0000-0001-5402-353X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0166-3542 |
| ispartof | Antiviral research, 2020-07, Vol.179, p.104811-104811, Article 104811 |
| issn | 0166-3542 1872-9096 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7188648 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Animals Antiviral Agents - pharmacology Antiviral therapy Betacoronavirus - drug effects Chlorocebus aethiops Coronavirus Infections - drug therapy Coronavirus Infections - immunology Coronavirus Infections - virology COVID-19 Humans Immunity, Innate Innate immune Interferon Interferon Type I - pharmacology Interferon-alpha - pharmacology Interferon-beta - pharmacology Pandemics Pneumonia, Viral - drug therapy Pneumonia, Viral - immunology Pneumonia, Viral - virology Recombinant Proteins - pharmacology SARS-CoV-2 Severe Acute Respiratory Syndrome - drug therapy Severe Acute Respiratory Syndrome - immunology Severe Acute Respiratory Syndrome - virology Vero Cells Viral Load - drug effects Virus Replication - drug effects |
| title | Antiviral activities of type I interferons to SARS-CoV-2 infection |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T10%3A11%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antiviral%20activities%20of%20type%20I%20interferons%20to%20SARS-CoV-2%20infection&rft.jtitle=Antiviral%20research&rft.au=Mantlo,%20Emily&rft.date=2020-07-01&rft.volume=179&rft.spage=104811&rft.epage=104811&rft.pages=104811-104811&rft.artnum=104811&rft.issn=0166-3542&rft.eissn=1872-9096&rft_id=info:doi/10.1016/j.antiviral.2020.104811&rft_dat=%3Cproquest_pubme%3E2398154165%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2398154165&rft_id=info:pmid/32360182&rft_els_id=S0166354220302254&rfr_iscdi=true |